McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Quest Diagnostics (DGX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) second-quarter results are likely to have reflected the solid base business performance and benefits from acquisitions.
Is AmerisourceBergen (ABC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.
Should Value Investors Buy Laboratory Corp. of America (LH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Add McKesson (MCK) to Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson's (MCK) Latest Launch to Give Access to OTC Products
by Zacks Equity Research
McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.
McKesson (MCK) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $414.09, marking a -0.4% move from the previous day.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $391.25, marking a -1.45% move from the previous day.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
McKesson (MCK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $389.22 in the latest trading session, marking a +1.2% move from the prior day.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.
McKesson (MCK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.42% and 1.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's How Inter Parfums (IPAR) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
Inter Parfums' (IPAR) Q1 earnings are expected to reflect gains from robust top-line growth, strength across brands, expansions and product launches.
McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Staar Surgical (STAA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 63.64% and 10.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $361, marking a +1.97% move from the previous day.
SmileDirectClub (SDC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
SmileDirectClub (SDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.